GlassScriptPhysician profile
Sanjay M Chavda
NPI 1437124484
$9,499.15
in general payments reported to CMS, 2019-2025
45 companies · $1,388 in 2025
The $1,388 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,280 · 2020: $2,252 · 2021: $1,489 · 2022: $1,106 · 2023: $584 · 2024: $1,401 · 2025: $1,388.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,373.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,372.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,611.51 | 2019-2025 | Fasenra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $1,370.72 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Jazz Pharmaceuticals INC. | $1,146.82 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $767.38 | 2019-2024 | Ofev |
| Actelion Pharmaceuticals US, INC. | $747.58 | 2019-2025 | Opsumit, Uptravi |
| Amgen INC. | $440.04 | 2019-2025 | Otezla, Repatha, Otezla |
| Regeneron Healthcare Solutions, INC. | $428.17 | 2019-2025 | Dupixent |
| Genzyme Corporation | $275.27 | 2021-2025 | |
| Lilly USA, LLC | $238.28 | 2020-2024 | Mounjaro, Jardiance, Emgality |
| United Therapeutics Corporation | $218.50 | 2020-2025 | Tyvaso, Tyvaso |
| Baxter Healthcare | $175.94 | 2022-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Insulet Corporation | $172.42 | 2020-2024 | Omnipod |
| Merck Sharp & Dohme LLC | $171.78 | 2019-2025 | Winrevair, Verquvo, Belsomra |
| Grifols USA, LLC | $171.76 | 2019-2025 | Prolastin-C Liquid |
| Mallinckrodt Hospital Products INC. | $154.66 | 2022 |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $152.61 | 2020-2022 | |
| Novo Nordisk INC | $128.21 | 2020-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $124.34 | 2020-2025 | Glassia |
| Shire North American Group INC | $89.80 | 2019 | |
| Mylan Specialty L.P. | $77.85 | 2019-2024 | Yupelri |
| Novartis Pharmaceuticals Corporation | $76.40 | 2024-2025 | |
| Viatris Specialty LLC | $68.93 | 2025 | Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $67.92 | 2021-2023 | |
| Genentech USA, INC. | $55.29 | 2019 | |
| Dexcom, INC. | $50.41 | 2021-2024 | Dexcom G6 Transmitter |
| Medtronic, INC. | $50.00 | 2021 | |
| Amarin Pharma, INC. | $48.96 | 2020-2021 | |
| Verona Pharma, INC. | $44.82 | 2025 | Ohtuvayre |
| Ani Pharmaceuticals, INC. | $38.89 | 2025 | Purified Cortrophin Gel |
| Pulmonx Corporation | $38.38 | 2025 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Abbvie INC. | $29.62 | 2022-2024 | |
| Sunovion Pharmaceuticals INC. | $27.50 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $25.87 | 2021-2022 | |
| Pfizer INC. | $24.86 | 2019-2021 | |
| Csl Behring | $24.46 | 2020 | |
| Si-Bone, INC. | $21.35 | 2020 | |
| Allergan, INC. | $21.00 | 2019 | |
| Xeris Pharmaceuticals, INC. | $20.26 | 2025 | Gvoke Hypopen |
| Gilead Sciences, INC. | $16.38 | 2021 | |
| Philips North America LLC | $14.97 | 2022 | |
| Advanced Respiratory, INC | $14.79 | 2021 | |
| Inspire Medical Systems, INC. | $14.06 | 2025 | Inspire |
| Idorsia Pharmaceuticals US INC | $13.85 | 2025 | Quviviq |
| Axsome Therapeutics, INC. | $13.63 | 2025 | Sunosi |
| Paratek Pharmaceuticals, INC. | $12.91 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjay Chavda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.